Tilray | TRLY - Pre Tax Profit


Tilray reported $-39.96M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Acasti Pharma USD -2.88M 564K Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Aurora Cannabis CAD 11.41M 12.99M Mar/2026
Avita Medical AUD -11.64M 12.13M Dec/2025
Canopy Growth CAD -157.96M 95.71M Mar/2026
Cronos Group USD 18.14M 30.52M Mar/2026
Dianthus Therapeutics USD -40.83M 23.6M Mar/2026
Divis Laboratories Ltd INR 11.8B 2.17B Jun/2026
Ionis Pharmaceuticals USD -114M 21M Jun/2026
IQVIA Holdings USD 301M 5.92B Jun/2026
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
Moderna USD -1.33B 535M Mar/2026
Organigram Holdings CAD -921K 40.8M Mar/2026
Organon & Co USD 183M 30M Jun/2026
Revvity USD 187.24M 137.25M Jun/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Tilray USD -39.96M 39.19M Sep/2025
Viatris USD -247.3M 95.7M Mar/2026
Xeris Pharmaceuticals USD 2.23M 8.85M Mar/2026
Zealand Pharma A/S -394M 12.5M Mar/2026